Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Capital Expenditures (2022)

Historic Capital Expenditures for BioXcel Therapeutics (BTAI) over the last 1 years, with Q2 2022 value amounting to $19000.0.

  • BioXcel Therapeutics' Capital Expenditures changed N/A to $19000.0 in Q2 2022 from the same period last year, while for Sep 2023 it was $19000.0, marking a year-over-year change of. This contributed to the annual value of $20000.0 for FY2023, which is 8561.15% down from last year.
  • Per BioXcel Therapeutics' latest filing, its Capital Expenditures stood at $19000.0 for Q2 2022.
  • BioXcel Therapeutics' 5-year Capital Expenditures high stood at $120000.0 for Q1 2022, and its period low was $19000.0 during Q2 2022.